Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ALX Oncology Holdings Inc. - Common Stock (NQ:ALXO)

1.980 -0.050 (-2.46%)
Streaming Delayed Price Updated: 9:54 AM EDT, May 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 31,161
Open 2.040
Bid (Size) 1.970 (400)
Ask (Size) 1.990 (500)
Prev. Close 2.030
Today's Range 1.970 - 2.055
52wk Range 0.4040 - 2.660
Shares Outstanding 40,869,135
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
ALX Oncology Q1 Earnings Call Highlights ↗
ALX Oncology (NASDAQ:ALXO) executives used the company’s first-quarter 2026 earnings call to highlight new clinical data for its lead CD47 blocker, evorpacept, and to provide updates on its... 
Via MarketBeat
Topics Earnings
ALX Oncology Holdings Inc (NASDAQ:ALXO) Beats Q1 Estimates and Unveils Promising Breast Cancer Data ↗
Via Chartmill

Performance

YTD
+72.2%
+72.2%
1 Month
+13.1%
+13.1%
3 Month
-20.2%
-20.2%
6 Month
+54.7%
+54.7%
1 Year
+311.6%
+311.6%

More News

Read More
News headline image
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026
From ALX Oncology
Via GlobeNewswire
ALX Oncology (NASDAQ:ALXO) Extends Cash Runway to 2028, Refines Evorpacept Strategy After Q4 Earnings ↗
Via Chartmill
News headline image
ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology (ALXO) Q4 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Announces Pricing of Underwritten Offering
From ALX Oncology
Via GlobeNewswire
News headline image
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting
From ALX Oncology
Via GlobeNewswire
News headline image
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
Via FinancialNewsMedia
News headline image
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
From FN Media Group LLC
Via GlobeNewswire
News headline image
ALX Oncology to Present at Upcoming Investor Conferences
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Holdings Inc (NASDAQ:ALXO) Reports Wider-Than-Expected Q3 2025 Loss Amid Promising Clinical Data ↗
Via Chartmill
News headline image
ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From ALX Oncology
Via GlobeNewswire
News headline image
Earnings Scheduled For November 7, 2025 ↗
Via Benzinga
News headline image
Examining the Future: ALX Oncology Holdings's Earnings Outlook ↗
Via Benzinga
News headline image
ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
From ALX Oncology
Via GlobeNewswire

Frequently Asked Questions

Is ALX Oncology Holdings Inc. - Common Stock publicly traded?
Yes, ALX Oncology Holdings Inc. - Common Stock is publicly traded.
What exchange does ALX Oncology Holdings Inc. - Common Stock trade on?
ALX Oncology Holdings Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ALX Oncology Holdings Inc. - Common Stock?
The ticker symbol for ALX Oncology Holdings Inc. - Common Stock is ALXO on the Nasdaq Stock Market
What is the current price of ALX Oncology Holdings Inc. - Common Stock?
The current price of ALX Oncology Holdings Inc. - Common Stock is 1.980
When was ALX Oncology Holdings Inc. - Common Stock last traded?
The last trade of ALX Oncology Holdings Inc. - Common Stock was at 05/14/26 09:54 AM ET
What is the market capitalization of ALX Oncology Holdings Inc. - Common Stock?
The market capitalization of ALX Oncology Holdings Inc. - Common Stock is 80.92M
How many shares of ALX Oncology Holdings Inc. - Common Stock are outstanding?
ALX Oncology Holdings Inc. - Common Stock has 81M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.